What is Thymosin Alpha-1 used for?

Thymosin Alpha-1 is approved in many countries for treating chronic hepatitis B and C, enhancing vaccine responses, and providing immune support in various conditions including cancer adjuvant therapy.

Is Thymosin Alpha-1 safe?

Thymosin Alpha-1 has an excellent safety profile with decades of use in approved markets. Common side effects are mild, primarily injection site reactions. It should be used with caution in autoimmune conditions and transplant recipients.

Why isn't Thymosin Alpha-1 approved in the US or UK?

Regulatory approval requires specific clinical trials meeting each agency's standards. While Tα1 has extensive data and is approved in over 35 countries, it has not completed the FDA or MHRA approval processes. It has orphan drug designations for some conditions.

Can Thymosin Alpha-1 help with COVID-19?

Some studies have investigated Tα1 for COVID-19 immune support. While there is biological rationale for its use, definitive evidence from large controlled trials is limited. It has been used in clinical settings in some countries during the pandemic.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Immune & Inflammatory•Updated 2026-02-01•5 min read

What Is Thymosin Alpha-1? Benefits, Research & Safety

A thymic peptide with potent immunomodulatory properties, approved in some countries for treating viral hepatitis and as an immune adjuvant.

Share:X Post LinkedIn

Also known as:

Tα1

TA1

Zadaxin

BModerate human evidenceUK: Unlicensed (UK)WADA: Sport status unclear

UK summary: Not a licensed UK medicine. Licensed in 35+ other countries (Zadaxin) for chronic hepatitis B/C and as an immune adjuvant. UK readers should not conflate 'approved elsewhere' with 'available on the NHS'. Sport status is uncertain — confirm before competition.

Quick Facts

Overview

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue. It plays a crucial role in immune system function, particularly in the maturation and differentiation of T lymphocytes. The thymus gland, where T cells mature, naturally produces this peptide as part of its immunological functions. Thymosin Alpha-1 has been extensively studied for its immunomodulatory properties and is approved as a pharmaceutical drug in several countries (marketed as Zadaxin) for the treatment of chronic hepatitis B and C, as an adjuvant to hepatitis B vaccination, and for immune enhancement in certain cancer treatments and immunodeficiency conditions. The peptide works by enhancing the function of dendritic cells and T cells, modulating cytokine production, and supporting both innate and adaptive immune responses. Unlike many immunostimulants, Tα1 appears to have immunomodulatory rather than purely immunostimulatory effects, helping to balance immune responses rather than simply amplifying them. While approved in numerous countries including China, Philippines, and several other Asian and European nations, Thymosin Alpha-1 has not achieved FDA approval in the United States, though it has received orphan drug designation for certain indications.

Evidence standards summary

Thymosin Alpha-1 — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

BModerate human evidenceOverall grade against our evidence grading methodology.

Not a licensed UK medicine. Licensed in 35+ other countries (Zadaxin) for chronic hepatitis B/C and as an immune adjuvant. UK readers should not conflate 'approved elsewhere' with 'available on the NHS'. Sport status is uncertain — confirm before competition.

02Human evidence grade

BModerate human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed. Available through specialist channels in some cases.
EU: Approved in some member states; orphan drug designation for certain conditions.
Notes: Thymosin Alpha-1 (Zadaxin) is approved in over 35 countries including China, Philippines, and several European and South American nations. It is not FDA approved in the US. Orphan drug designations exist for certain conditions.

05Approved medical uses

Chronic hepatitis B and C (licensed as Zadaxin in 35+ countries — NOT MHRA-licensed in the UK).
Immune-adjuvant in certain cancer treatments (in the licensed jurisdictions).
Immunocompromised-state support (in the licensed jurisdictions).

06Unapproved / promotional claims

Boosts immune function in healthy adults.
Treats long COVID or chronic fatigue syndrome.
Cures autoimmune disease.
Safe and effective for general wellness.

07Common internet claims

Marketed by private 'immune optimisation' clinics for everyday wellness.
Sold by online retailers as research-only injection.
Promoted as a long-COVID / chronic-fatigue therapy.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Approved hepatitis treatment with strong safety record”	B	Yes	Moderate	Zadaxin is licensed for chronic hepatitis B/C in many jurisdictions; not licensed in the UK; UK access is not via standard NHS routes.
“Boosts immunity for everyday wellness”	E	No	High	Immune-modulator use in healthy adults is not a licensed indication; 'boosts immunity' is a recognised regulatory red-flag phrase.
“Cures long COVID / chronic fatigue”	E	No	High	Promising mechanistic interest exists but robust RCT evidence for these specific indications is lacking.
“Safe — no serious adverse events”	B	Yes	Moderate	Safety in licensed indications is well documented; caution in autoimmune disease and transplant recipients.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Injection-site reactions.
Theoretical risk of triggering autoimmune flares.
Caution required in transplant recipients (immune-stimulation conflict).
Unknown long-term effects when used outside licensed indications.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Unlicensed (UK)

Not licensed. Available through specialist channels in some cases.

Read the full UK legal guide → Are peptides legal in the UK?

14EU legal position

Approved in some member states; orphan drug designation for certain conditions.

15What this page cannot tell you

Whether a UK-purchased vial actually contains TA1 at the labelled concentration.
Whether immune stimulation in a healthy adult provides any benefit.
How it interacts with immunosuppressants in transplant or autoimmune patients.
Whether long COVID or chronic fatigue benefit is real — RCT evidence does not yet exist.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

No UK MHRA marketing authorisation despite extensive international use.
Long COVID and chronic fatigue RCT evidence not yet published.
Optimal dose / duration in unlicensed indications unestablished.
Healthy-adult outcomes data effectively absent.

19Safer alternatives / established care pathways

GP review for any chronic infection, immunodeficiency, or post-viral syndrome.
Licensed antivirals for hepatitis B and C via NHS hepatology service.
NHS long-COVID clinic referral (where available) for evidence-based multidisciplinary care.
Standard vaccination schedule for general immune support.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is Thymosin Alpha-1 a licensed UK medicine for any condition?
If I'm being offered it for an immune indication, is the prescriber registered in the UK and what's the supply chain?
Are there licensed UK alternatives for my underlying condition?
What is the WADA / UKAD position if I compete?

Discovery & History

Thymosin Alpha-1 was discovered in the 1970s by Allan Goldstein at the University of Texas Medical Branch as part of research into thymic hormones. The thymus gland had been known to be essential for immune function, and researchers were working to identify the specific factors responsible for its immunological activity. Goldstein and colleagues isolated "thymosin fraction 5," a crude extract of thymic peptides that showed immune-enhancing properties. Further purification identified Thymosin Alpha-1 as one of the most active components of this fraction. The peptide was sequenced and subsequently synthesized, allowing for detailed research into its mechanisms and potential clinical applications. Studies revealed its role in T cell maturation and immune regulation. Clinical development proceeded through the 1980s and 1990s, with trials for viral hepatitis, cancer adjuvant therapy, and immune deficiency. The peptide was approved in several countries beginning in the late 1990s. SciClone Pharmaceuticals (later acquired by others) developed Zadaxin, the commercial form of Thymosin Alpha-1, which has been marketed primarily in Asia where it is widely used for hepatitis treatment and immune support.

Mechanism of Action

Thymosin Alpha-1 exerts immunomodulatory effects through multiple mechanisms: **T Cell Maturation** Tα1 promotes the maturation and differentiation of T lymphocytes, particularly the development of CD4+ and CD8+ T cells. This enhances the body's adaptive immune capacity. **Dendritic Cell Activation** The peptide activates dendritic cells, which are crucial antigen-presenting cells that initiate adaptive immune responses. This enhances the immune system's ability to recognize and respond to pathogens. **Cytokine Modulation** Tα1 modulates the production of various cytokines, generally shifting toward a Th1 (cell-mediated) response while dampening excessive inflammation. It increases IL-2, IFN-γ, and other cytokines important for antiviral and antitumour immunity. **Toll-Like Receptor Activation** Research indicates that Tα1 activates certain Toll-like receptors (TLRs), enhancing innate immune recognition of pathogens. **Natural Killer Cell Enhancement** The peptide may enhance natural killer (NK) cell activity, contributing to antiviral and antitumour immunity. **Immunomodulatory Balance** Importantly, Tα1 appears to be immunomodulatory rather than purely immunostimulatory—it can help balance immune responses rather than simply amplifying them, potentially reducing autoimmune tendencies while enhancing pathogen responses.

Researched Benefits

Based on preclinical and clinical research findings:

1
Enhanced T cell function and maturation
2
Improved responses to viral infections (hepatitis B and C)
3
Vaccine response enhancement
4
Potential adjuvant effects in cancer therapy
5
Immune support in immunocompromised states
6
Possible benefits in sepsis and critical illness
7
Balanced immunomodulation rather than excessive stimulation

Claim vs Evidence

How popular claims about Thymosin Alpha-1 stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Approved hepatitis treatment with strong safety record”	B	Yes	Moderate	Zadaxin is licensed for chronic hepatitis B/C in many jurisdictions; not licensed in the UK; UK access is not via standard NHS routes.
“Boosts immunity for everyday wellness”	E	No	High	Immune-modulator use in healthy adults is not a licensed indication; 'boosts immunity' is a recognised regulatory red-flag phrase.
“Cures long COVID / chronic fatigue”	E	No	High	Promising mechanistic interest exists but robust RCT evidence for these specific indications is lacking.
“Safe — no serious adverse events”	B	Yes	Moderate	Safety in licensed indications is well documented; caution in autoimmune disease and transplant recipients.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	1.6 mg subcutaneously (standard pharmaceutical dose)
Frequency	Twice weekly for most approved indications
Duration	Variable depending on indication; often 6-12 months for hepatitis
Notes	Thymosin Alpha-1 is an approved medication in several countries. Dosing follows established pharmaceutical protocols. Use should be under medical supervision with appropriate monitoring.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (approved route)

Half-Life	Stability
Approximately 2 hours	Pharmaceutical formulations (Zadaxin) have defined stability; lyophilised forms should be stored appropriately

Safety Profile & Known Risks

Commonly Reported Side Effects

Injection site reactions (mild)
Fatigue
Mild flu-like symptoms
Generally very well tolerated

Rare Risks & Concerns

Allergic reactions (rare)
Theoretical concerns in autoimmune conditions
Limited data in pregnancy

Contraindications

Known hypersensitivity to Thymosin Alpha-1
Organ transplant recipients (immune stimulation may risk rejection)
Certain autoimmune conditions (use with caution)
Pregnancy (limited data)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed. Available through specialist channels in some cases.

🇪🇺 European Union

Approved in some member states; orphan drug designation for certain conditions.

Thymosin Alpha-1 (Zadaxin) is approved in over 35 countries including China, Philippines, and several European and South American nations. It is not FDA approved in the US. Orphan drug designations exist for certain conditions.

Clinical Studies Summary

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.

Tα1 can regulate the balance of immune cells and alleviate immune suppression in SAP patients, including increasing CD4+ T cells and CD4+/CD8+ ratios. Tα1 may exert anti-inflammatory and extrapancreatic infection-preventive effects on SAP patients and improve their condition or prognosis. More researches are needed to validate the results.

Front Immunol. 2025View on PubMed

The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.

Our study suggests that treatment with thymosin alpha-1 may reduce mortality rate in moderate to critical COVID-19 patients. Randomized clinical trials (RCTs) are still required to verify the findings of our study.

Inflammopharmacology. 2023View on PubMed

The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.

ETV plus Tα1 might lead to a higher clinical response and a lower comprehensive adverse reaction rate in HBV-related patients with cirrhosis, compared to ETV alone. However, the whole patients included in this meta-analysis were from Chinese mainland, so that more worldwide RCTs with a larger sample size are needed to verify the current findings.

BMC Gastroenterol. 2020View on PubMed

Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection.

We assessed the cumulative findings with trial sequential analysis to control for random errors.

Cochrane Database Syst Rev. 2013View on PubMed

Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.

Based on substantial evidence from clinical trials, Tα1 emerges as a well-tolerated and effective immune modulator. The FDA›s restriction appears unfounded, as Tα1 has shown safety and efficacy beyond the initially specified conditions. Urgent attention and intervention are warranted to ensure the continued availability of this life-saving peptide through prescription.

Altern Ther Health Med. 2024View on PubMed

Aging and Thymosin Alpha-1.

It represents a promising therapeutic approach to counteract age-related immune dysfunction and inflammation, potentially by slowing the aging process. Further research is needed to validate its long-term efficacy and safety in geriatrics.

Int J Mol Sci. 2025View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

15 of 17 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Thymosin-α1 for Recurrent Implantation Failure

PHASE2/PHASE3

Status: Recruiting · 136 participants · Fakih IVF Fertility Center

Conditions: Recurrent Implantation Faliure

No results postedNCT07675980

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

PHASE2

Status: Recruiting · 52 participants · Beijing Friendship Hospital

Conditions: MCRC

No results postedNCT06829355

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

PHASE1

Status: Recruiting · 75 participants · The Methodist Hospital Research Institute

Conditions: Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination

No results postedNCT06821100

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Status: Not Yet Recruiting · 40 participants · Xuanwu Hospital, Beijing

Conditions: Resectable Non-Small-Cell Lung Cancer

No results postedNCT06607926

Immuno-effect of Tα1 for Stage I NSCLC

Status: Recruiting · 40 participants · Yousheng Mao

Conditions: Non Small Cell Lung Cancer

No results postedNCT06598839

Thymosin Alpha-1 for irAE Secondary to ICIs

PHASE4

Status: Unknown · 40 participants · Jun Wang

Conditions: IrAE

No results postedNCT06178146

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

PHASE2

Status: Active Not Recruiting · 114 participants · Sun Yat-sen University

Conditions: Non-small Cell Lung Cancer

No results postedNCT06139419

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

PHASE2

Status: Recruiting · 55 participants · Sun Yat-sen University

Conditions: Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor

No results postedNCT07644897

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Status: Unknown · 200 participants · Nanjing Medical University

Conditions: Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy

No results postedNCT05487469

Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Status: Recruiting · 330 participants · Nanjing Medical University

Conditions: Acute Aortic Syndrome, Aortic Dissection Type a

No results postedNCT05339529

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

EARLY_PHASE1

Status: Completed · 20 participants · Shanghai Public Health Clinical Center

Conditions: HIV-1-infection

No results postedNCT04963712

Long-term Prognosis of Patients With Sepsis After Immunotherapy

N/A

Status: Not Yet Recruiting · 900 participants · Sun Yat-sen University

Conditions: Long-term Effects of Thymosin Alpha 1 Treatment

No results postedNCT04901104

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Thymosin Alpha-1?

Source research-grade Thymosin Alpha-1 from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Thymosin Alpha-1

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is Thymosin Alpha-1 a licensed UK medicine for any condition?
If I'm being offered it for an immune indication, is the prescriber registered in the UK and what's the supply chain?
Are there licensed UK alternatives for my underlying condition?
What is the WADA / UKAD position if I compete?

Quick Facts

Overview

01Evidence snapshot

02Human evidence grade

03Preclinical evidence grade

04Regulatory status

05Approved medical uses

06Unapproved / promotional claims

07Common internet claims

08Claim vs evidence

09Safety uncertainty score

10Known adverse signals

11Drug-interaction uncertainty

12Anti-doping status

13UK legal position

14EU legal position

15What this page cannot tell you

16Last reviewed

17Citation quality score

18Research gaps

19Safer alternatives / established care pathways

20Doctor discussion prompts

Questions to ask a qualified clinician

Discovery & History

Mechanism of Action

Researched Benefits

Claim vs Evidence

Theoretical Dosing & Protocols

Administration Routes

Safety Profile & Known Risks

Commonly Reported Side Effects

Rare Risks & Concerns

Contraindications

UK & EU Regulatory Context

🇬🇧 United Kingdom

🇪🇺 European Union

Clinical Studies Summary

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.

The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.

The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.

Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection.

Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.

Aging and Thymosin Alpha-1.

Registered Trials & Regulatory Status

Thymosin-α1 for Recurrent Implantation Failure

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Immuno-effect of Tα1 for Stage I NSCLC

Thymosin Alpha-1 for irAE Secondary to ICIs

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Adverse event reports (FDA FAERS)

Looking for Thymosin Alpha-1?

Frequently Asked Questions

What is Thymosin Alpha-1 used for?

Is Thymosin Alpha-1 safe?

Why isn't Thymosin Alpha-1 approved in the US or UK?

Can Thymosin Alpha-1 help with COVID-19?

Questions to ask a qualified clinician about Thymosin Alpha-1

UK regulatory & safety context

Are peptides legal in the UK?

Unlicensed peptide risks

Related Research Guides

Peptides for Immune Support

Related Peptides

TB-500

Thymosin Beta-4

LL-37

Explore More Peptides